{"id":"Z17","lang":"zh","question":"AstraZeneca 跟 insitro 的合作，公開的簽約金和最高里程碑金是多少？","answer":[{"text":"insitro 於 2026 年 10 月 15 日公告與 AstraZeneca 合作，公開的簽約金承諾為 4,000 萬美元，潛在里程碑最高約 14.6 億美元。","fact_ids":["f1","f2"]},{"text":"公告另列未來全球商業銷售的個位數百分比權利金。","fact_ids":["f3"]}],"facts":[{"id":"f1","claim":"Upfront commitment","value":"USD 40,000,000","as_of":"2026-10-15","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","quote":"$40 million upfront"},{"id":"f2","claim":"Potential milestone ceiling","value":"Approximately USD 1,460,000,000","as_of":"2026-10-15","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","quote":"$1.46 billion"},{"id":"f3","claim":"Royalties","value":"Single-digit royalties on potential global commercial sales","as_of":"2026-10-15","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","quote":"single-digit royalties"}],"undisclosed":{"text":"這份公開新聞稿沒有揭露簽約金是否已實際入帳，也沒有公布各里程碑門檻與精確權利金比率。","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","as_of":"2026-10-22","quote":"will receive","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["公告是付款承諾；實際收款與里程碑細項查無。"]}